Skip to content

Qinggan Jiangya Capsule in the treatment of primary hypertension (grade 1-2) (anger hyperactivity liver kidney yin deficiency syndrome) the single arm, open, multicenter clinical trial

Qinggan Jiangya Capsule in the treatment of primary hypertension (grade 1-2) (anger hyperactivity liver kidney yin deficiency syndrome) the single arm, open, multicenter clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015022
Enrollment
Unknown
Registered
2018-03-01
Start date
2017-11-22
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hypertension (grade 1-2)

Interventions

experimental group:Qinggan Jiangya capsule and Songling Xuemai Kang capsule analogue

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The first diagnosis of the patients with primary hypertension 1-2; (2) In accordance with Chinese medicine, anger hyperactivity liver kidney yin deficiency syndrome diagnosis; (3) 140mmHg =Sitting systolic pressure=179mmHg, and (or) 90mmHg=sitting diastolic blood pressure = 109mmHg; (4) Aged between 18-75 years; (5) The person who voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Unstable angina pectoris, cardio cerebral vascular accident, acute myocardial infarction or heart failure patients; (2) Those who have known or suspected secondary hypertension; (3) Type 1 diabetes or standardized oral hypoglycemic drugs were still not well controlled (fasting plasma glucose >11 mmol/L), type 2 diabetes mellitus, complications (nephropathy, peripheral neuropathy, etc.); (4) The drug absorbers may be affected by gastrointestinal or gastrointestinal surgery; (5) Combined with other severe primary diseases or malignant tumors such as liver, kidney and hematopoietic system, ALT and AST exceed 1.5 times the upper limit of normal value, and Cr exceeds the upper limit of normal value; (6) Allergic constitution, test drug or its component allergy; (7) Women of lactation and women who are pregnant or preparing for pregnancy in the near future; (8) Excessive smoking (>10 / day), excessive drinking (drinking 14 units per week alcohol: 1 units = beer 285 ml, or spirits 25 ml, or wine about 100 ml), or occupational factors and other factors that affect blood pressure controllers; (9) Suspect or indeed have a history of alcohol abuse or drug abuse. Or according to the researchers' judgement, other diseases or situations that may reduce the possibility of entry or make the entry complex, such as frequent changes in working environment, are likely to cause loss of visits.

Design outcomes

Primary

MeasureTime frame
The average change of systolic pressure / diastolic pressure in the second, fourth week position compared with baseline;

Countries

China

Contacts

Public ContactLinjing Zhang

Dongzhimen Hospital Beijing University of Chinese Medicine

lijingzhang@263.net+86 13501214395

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026